Volume 8, Issue 1, Pages (July 2003)

Slides:



Advertisements
Similar presentations
Figure 1. Analysis of truncated-UL13 protein prokaryotic expression and UL13 expression in DEV-infected DEF cells. (A) Expression and purification of the.
Advertisements

Volume 127, Issue 4, Pages (October 2004)
Molecular Diagnosis of Epstein-Barr Virus-Related Diseases
Down-regulation of HLA-G boosted natural killer cell-mediated cytolysis in JEG-3 cells cultured in vitro  Li Li Sun, M.Sc., Yibing Han, Ph.D., Jian Hui.
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Volume 127, Issue 4, Pages (October 2004)
Self-Excising Retroviral Vectors Encoding the Cre Recombinase Overcome Cre- Mediated Cellular Toxicity  Daniel P. Silver, David M. Livingston  Molecular.
A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia by Anja Ehrhardt, Hui.
Skin-Specific Expression of ank-393, a Novel Ankyrin-3 Splice Variant
Stimulation of V(D)J recombination by histone acetylation
Volume 10, Issue 4, Pages (October 2004)
Robert E. White, Richard Wade-Martins, Michael R. James 
Volume 16, Issue 3, Pages (March 2008)
Volume 12, Issue 6, Pages (December 2005)
Expression of Indoleamine 2,3-Dioxygenase in Dermal Fibroblasts Functions as a Local Immunosuppressive Factor  Yunyuan Li, Edward E. Tredget, Ruhangiz.
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Volume 44, Issue 4, Pages (April 2006)
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Silencing in Yeast rDNA Chromatin
Improved system for helper-dependent adenoviral vector production
Claire Soudais, Sylvie Boutin, Eric J. Kremer  Molecular Therapy 
Volume 2, Issue 4, Pages (October 2000)
Volume 9, Issue 6, Pages (June 2004)
Complete Cure of Persistent Virus Infections by Antiviral siRNAs
Transgene Expression in the Brain Stem Effected by Intramuscular Injection of Polyethylenimine/DNA Complexes  Shu Wang, Nan Ma, Shujun J. Gao, Hanry Yu,
Volume 10, Issue 1, Pages (July 2004)
Volume 9, Issue 4, Pages (April 2004)
Volume 115, Issue 4, Pages (October 1998)
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Yongli Bai, Chun Yang, Kathrin Hu, Chris Elly, Yun-Cai Liu 
Volume 13, Issue 2, Pages (February 2006)
Transcriptional Control of the Mouse Col7a1 Gene in Keratinocytes: Basal and Transforming Growth Factor-β Regulated Expression  Michael Naso, Jouni Uitto,
Vaccinia virus as a subhelper for AAV replication and packaging
Volume 9, Issue 6, Pages (December 1998)
Volume 18, Issue 2, Pages (April 2005)
Volume 4, Issue 6, Pages (December 2001)
Regulation of α-Synuclein Expression by Poly (ADP Ribose) Polymerase-1 (PARP-1) Binding to the NACP-Rep1 Polymorphic Site Upstream of the SNCA Gene  Ornit.
Andrew J Henderson, Ruth I Connor, Kathryn L Calame  Immunity 
Volume 8, Issue 6, Pages (December 2003)
Molecular Therapy - Methods & Clinical Development
Transcriptional Regulation of ATP2C1 Gene by Sp1 and YY1 and Reduced Function of its Promoter in Hailey–Hailey Disease Keratinocytes  Hiroshi Kawada,
Expression and localization of histamine H2 receptor messenger RNA in human nasal mucosa  Noriko Hirata, MDa, Kazuhiko Takeuchi, MDa, Kotaro Ukai, MDa,
Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy 
Volume 8, Issue 1, Pages (July 2003)
Development of an HIV-Based cDNA expression cloning system
Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus  Zong Sheng Guo, Zuqiang.
Volume 12, Issue 5, Pages (November 2005)
Barbara S Nikolajczyk, J.Aquiles Sanchez, Ranjan Sen  Immunity 
Volume 2, Issue 4, Pages (October 1998)
Volume 3, Issue 1, Pages (January 2001)
Volume 21, Issue 1, Pages (January 2013)
Ly6d-L, a Cell Surface Ligand for Mouse Ly6d
Hongli Lin, Xiangmei Chen, Jianzhong Wang, Zhiheng Yu 
Volume 13, Issue 5, Pages (May 2006)
RNA Polymerase II Activity of Type 3 Pol III Promoters
Molecular Therapy - Nucleic Acids
Template Switching by RNA Polymerase II In Vivo
Effect of Genome Size on AAV Vector Packaging
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 4, Issue 6, Pages (December 2001)
Development of an HIV-Based cDNA expression cloning system
Changyu Zheng, Bruce J. Baum  Molecular Therapy 
Volume 10, Issue 6, Pages (December 2004)
Jiamiao Lu, Feijie Zhang, Mark A Kay  Molecular Therapy 
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Generate TALE/TALEN as Easily and Rapidly as Generating CRISPR
Volume 9, Issue 2, Pages (February 2004)
Volume 9, Issue 5, Pages (May 2004)
Volume 3, Issue 4, Pages (April 2001)
Volume 14, Issue 1, Pages (July 2006)
Presentation transcript:

Volume 8, Issue 1, Pages 158-166 (July 2003) A simple and efficient method for constructing an adenoviral cDNA expression library  Kazuteru Hatanaka, Shumpei Ohnami, Kimiko Yoshida, Yoshiaki Miura, Kazuhiko Aoyagi, Hiroki Sasaki, Masahiro Asaka, Masaaki Terada, Teruhiko Yoshida, Kazunori Aoki  Molecular Therapy  Volume 8, Issue 1, Pages 158-166 (July 2003) DOI: 10.1016/S1525-0016(03)00138-2 Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Construction of an adenovirus cDNA expression library. The linearized shuttle plasmid cDNA library is mixed with left-end-digested adenoviral DNA-TPC, and Cre recombinase produces the full-length recombinant adenoviral DNA library in vitro. The Cre-treated DNA library is transfected into high-efficiency virus-producing 293 cells, and a recombinant adenovirus cDNA library is produced. Molecular Therapy 2003 8, 158-166DOI: (10.1016/S1525-0016(03)00138-2) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Transfection method for 293 cells. 2–10 μg of adenoviral genomic DNA containing CMV-AP was transfected into 293 cells in a six-well plate, and then the expression of the AP gene was evaluated. (a) Calcium phosphate (CellPhect Transfection Kit) using 10 μg of DNA. (b) Lipofection (Lipofectamine Plus reagent) using 6 μg of DNA. (c) Radiofrequency electroporation [31] (Gene Pulser II RF module) using 10 μg of DNA. (d) Polyethylenimine [32] using 6 μg of DNA. Molecular Therapy 2003 8, 158-166DOI: (10.1016/S1525-0016(03)00138-2) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 3 Enhancement of adenovirus production by terminal protein. (A) Experimental design of dilution experiment. The pAdCMV-EGFP were mixed with pAdCMV-AP or a shuttle plasmid library at various ratios, recombined with cS360loxP or DNA-TPC by Cre in vitro, and then transfected into parental 293 cells and their high-efficiency virus-producing clones. After 6–9 days, 7% of viral lysates was infected into A549 cells to detect an EGFP-expressing adenovirus. (B) EGFP expression in A549 cells at 48 h postinfection (×100 original magnification). Various ratios of pAdCMV-EGFP and pAdCMV-AP were recombined with left-end-digested DNA-TPC and then transfected into 293 clones. Titers of each adenoviral lysate, which were determined by the TCID50 assay [33], were 8.2 × 108 to 5.9 × 109 PFU/ml. (C) Southern blot analysis of adenoviral library DNA. Various ratios of pAdCMV-EGFP and shuttle plasmid library were recombined with left-end-digested DNA-TPC and then transfected into clone 38. Two micrograms of the EcoRI- (lanes 2 and 3) or XbaI-digested cell lysates (lanes 5 and 6) were analyzed by Southern blot hybridization with a 32P-labeled 0–1 mu + CMV promoter (left end) probe (lanes 1–3) or an EGFP probe (lanes 4–6). To examine the amount of ADVCMV-EGFP DNA within the total adenovirus DNA, the exposure time was adjusted to show the same band intensity in the control plasmid lane (10 ng of pAdCMV-EGFP) (lanes 1 and 4) of each film. The left side arrow indicates the band of the left end from the total adenoviral library DNA at 30 (lane 2) and 300 (lane 3) dilutions. The right side arrow indicates the band of the left end and the EGFP gene from ADVCMV-EGFP at 30 (lane 5) and 300 (lane 6) dilutions. The ratio of ADVCMV-EGFP DNA within the total adenoviral DNA, which was determined by densitometry, was approximately 1:30 (lane 5:lane 2) and 1:300 (lane 6:lane 3). (D) PCR analysis of plasmid library and adenoviral library DNA. PCR amplification of six endogenous genes was carried out in DNA of the shuttle plasmid library and adenoviral library using specific primers. PCR products were confirmed by sequencing. Lane 1: RT-PCR using total RNA extracted from human T cells. Lane 2: shuttle plasmid library derived from human T cells. Lane 3: adenoviral library DNA converted from shuttle plasmid library. Lane 4: no DNA. (E) PCR analysis of adenoviral library DNA during multiple-round amplifications of viruses. Adenoviral library derived from human T cells was infected into 293 cells, and then the crude viral lysate was harvested and used to infect 293 cells. This process was repeated. PCR amplification of six endogenous genes was carried out in DNA of adenoviral libraries during three rounds of amplification using specific primers. Lane 1: adenovirus library DNA after first round of amplification. Lane 2: second round of amplification. Lane 3: third round of amplification. Molecular Therapy 2003 8, 158-166DOI: (10.1016/S1525-0016(03)00138-2) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 4 Screening of the viral cDNA library. (A) Strategy for identification of CD2 gene with adenoviral cDNA library. In the first-round screening, the shuttle plasmid library was divided into 96 cDNA pools (about 100 colonies/pool). Each pool was recombined with DNA-TPC by Cre in vitro and transfected into clone 38 cells in a 96-well collagen-coated microplate. After 8 days, cell lysate-infected AsPC-1 cells were examined by immunocytochemistry. In the second-round screening, each colony from a CD2-positive pool was again examined by the same procedure. (B) Southern blot analysis to estimate the frequency of CD2 plasmid. Various amounts of pAdCMV-CD2 and 1 μg of shuttle plasmid cDNA library constructed from human T cells were analyzed by Southern blot hybridization with a 32P-labeled CD2 cDNA probe. Lanes 1–7: pAdCMV-CD2 [lane 1, 1 μg; lane 2, 100 ng (1/10 of lane 1); lane 3, 10 ng (1/100); lane 4, 1 ng (1/1000); lane 5, 200 pg (1/5000); lane 6, 100 pg (1/10,000); lane 7, 20 pg (1/50,000)]. Lane 8: T cell shuttle plasmid library (1 μg). CD2 clone in human T cell cDNA library was estimated at less than 1/3000 by densitometry. (C) Immunocytochemistry for CD2. Library-infected AsPC-1 cells were stained with antibody to human CD2. Upper left: AsPC-1 cells showing positive staining. Upper right: AsPC-1 cells showing negative staining. Lower left: positive control (ADVCMV-CD2-infected AsPC-1 cells). Lower right: negative control (ADVCMV-EGFP-infected AsPC-1 cells). (D) PCR analysis to identify CD2 cDNA. Positive pools were analyzed by PCR using the same CD2-specific primers as in Fig. 3D. Lane 1: 500 bp ladder marker. Lane 2: DNA from a shuttle plasmid pool showing positive staining (from C, upper left). Lane 3: DNA from a shuttle plasmid pool showing negative staining (from C, upper right). Molecular Therapy 2003 8, 158-166DOI: (10.1016/S1525-0016(03)00138-2) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions